The Marketing Authorisation of Advanced Therapy Medicinal Products under the regulation of the European Union

• Main Authors: Mahalatchimy, Aurélie, Gilbert, Luc-Sylvain, Delage, Auxane, Nègre, Olivier
• Other Authors: Droits International, Comparé et Européen / Centre d'études et de recherches internationales et communautaires (CERIC) (DICE / CERIC), Droits International, Comparé et Européen (DICE), Aix Marseille Université (AMU)-Université de Pau et des Pays de l'Adour (UPPA)-Université de Toulon (UTLN)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Université de Pau et des Pays de l'Adour (UPPA)-Université de Toulon (UTLN)-Centre National de la Recherche Scientifique (CNRS), International Society for Cell & Gene Therapy, ANR-20-CE26-0007,I-BioLex,Fragmentation et défragmentation du droit des innovations biomédicales(2020), European Project: 965241,EuroGCT
• Format: Conference Object
• Language: English
• Published: HAL CCSD 2023
• Subjects: [SHS]Humanities and Social Sciences; [SHS.DROIT]Humanities and Social Sciences/Law; Norway; Iceland
• Online Access: https://shs.hal.science/halshs-04290539; https://shs.hal.science/halshs-04290539/document; https://shs.hal.science/halshs-04290539/file/Poster%20-%20ISCT%202023%20PARIS%20The%20marketing%20authorisation%20of%20advanced%20therapy%20medicinal%20product%20FINAL.pdf

Advanced Therapy Medicinal Products (ATMPs) is a European classification of medicinal products based on genes, cells and tissues specifically regulated in the European Union (EU) from the entry into force of Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on ATMPs. Any company wishing to market ATMPs within the EU must hold a Marketing Authorisation (MA) issued by the European Commission under the “centralised procedure”, after a single application to the European Medicines Agency (EMA) and its scientific assessment by the Committee for Advanced Therapies. The purpose of the MA is to ensure high quality, safety and efficacy for ATMPs, with a positive risk-benefit balance, to be commercialised. The MA is valid in the EU Member States, Iceland, Norway and Liechtenstein for a five-years period.From the adoption of the EU regulation, 24 ATMPs have been granted a marketing authorisation in the EU and the European Commission decision is pending for another one. There has been a clear increase in approvals from 2018, and most approved ATMPs are gene therapy medicinal products. Almost half of them benefited from expediting pathways or regulatory support schemes for (innovative) medicines to be commercialised in the EU. Nevertheless, MA has been withdrawn or not renewed for 7 of them. This poster will present the European regulatory requirements and pathways for ATMPs to obtain marketing authorisation, and discuss the challenges of their commercialisation.